1. Home
  2. KROS vs AMBC Comparison

KROS vs AMBC Comparison

Compare KROS & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • AMBC
  • Stock Information
  • Founded
  • KROS 2015
  • AMBC 1971
  • Country
  • KROS United States
  • AMBC United States
  • Employees
  • KROS N/A
  • AMBC N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • AMBC Property-Casualty Insurers
  • Sector
  • KROS Health Care
  • AMBC Finance
  • Exchange
  • KROS Nasdaq
  • AMBC Nasdaq
  • Market Cap
  • KROS 565.0M
  • AMBC 411.3M
  • IPO Year
  • KROS 2020
  • AMBC 1991
  • Fundamental
  • Price
  • KROS $15.62
  • AMBC $8.96
  • Analyst Decision
  • KROS Buy
  • AMBC Strong Buy
  • Analyst Count
  • KROS 14
  • AMBC 2
  • Target Price
  • KROS $20.56
  • AMBC $12.50
  • AVG Volume (30 Days)
  • KROS 412.4K
  • AMBC 509.7K
  • Earning Date
  • KROS 11-05-2025
  • AMBC 11-11-2025
  • Dividend Yield
  • KROS N/A
  • AMBC N/A
  • EPS Growth
  • KROS N/A
  • AMBC N/A
  • EPS
  • KROS 0.47
  • AMBC N/A
  • Revenue
  • KROS $232,844,000.00
  • AMBC $257,879,000.00
  • Revenue This Year
  • KROS $5,998.31
  • AMBC N/A
  • Revenue Next Year
  • KROS N/A
  • AMBC $19.44
  • P/E Ratio
  • KROS $33.74
  • AMBC N/A
  • Revenue Growth
  • KROS 85820.30
  • AMBC 148.44
  • 52 Week Low
  • KROS $9.12
  • AMBC $5.99
  • 52 Week High
  • KROS $72.37
  • AMBC $13.64
  • Technical
  • Relative Strength Index (RSI)
  • KROS 57.13
  • AMBC 57.12
  • Support Level
  • KROS $15.34
  • AMBC $8.40
  • Resistance Level
  • KROS $15.85
  • AMBC $9.03
  • Average True Range (ATR)
  • KROS 0.45
  • AMBC 0.29
  • MACD
  • KROS -0.02
  • AMBC -0.05
  • Stochastic Oscillator
  • KROS 57.08
  • AMBC 58.95

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About AMBC Ambac Financial Group Inc.

Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.

Share on Social Networks: